E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029263 |
E.1.2 | Term | Neurodermatitis |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the efficacy of dupilumab on itch response in patients with prurigo nodularis (PN), inadequately controlled on topical prescription therapy or when those therapies are not advisable |
|
E.2.2 | Secondary objectives of the trial |
- To demonstrate the efficacy of dupilumab on additional itch endpoints in patients with PN, inadequately controlled on topical prescription therapy or when those therapies are not advisable - To demonstrate efficacy of dupilumab on skin lesions of PN - To demonstrate the improvement in health-related quality of life - To evaluate safety outcome measures - To evaluate immunogenicity of dupilumab
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Must be 18 to 80 years of age, at the time of signing the informed consent. With a clinical diagnosis of PN defined by all of the following: - Diagnosed by a dermatologist for at least 3 months before the Screening visit - On the WI-NRS ranging from 0 to 10, patients must have an average worst itch score of ≥7 in the 7 days prior to Day1. - Patients must have a minimum of 20 PN lesions in total on both legs, and/or both arms and/or trunk, at Screening visit and Day 1 - History of failing a 2-week course of medium-to-superpotent topical corticosteroids (TCS) or when TCS are not medically advisable - Have applied a stable dose of topical emollient (moisturizer) once or twice daily for at least 5 out of the 7 consecutive days immediately before Day 1 Must be willing and able to complete a daily symptom eDiary for the duration of the study
|
|
E.4 | Principal exclusion criteria |
Participants are excluded from the study if any of the following criteria apply: - Presence of skin morbidities other than PN and mild atopic dermatitis that may interfere with the assessment of the study outcomes - PN secondary to medications - PN secondary to medical conditions such as neuropathy or psychiatric disease - Within 6 months before the screening visit, or documented diagnosis of moderate to severe AD from screening visit to randomization visit - Severe concomitant illness(es) under poor control that, in the investigator’s judgment, would adversely affect the patient’s participation in the study - Severe renal conditions (eg, patients with uremia and/or on dialysis) - Participants with uncontrolled thyroid disease. - Active tuberculosis or non-tuberculous mycobacterial infection, or a history of incompletely treated tuberculosis unless documented adequately treated - Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic infection, unless clinical and (if necessary) laboratory assessment have ruled out active infection before randomization. - Active chronic or acute infection (except HIV infection) requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before the screening visit and during the screening period - Known or suspected immunodeficiency - Active malignancy or history of malignancy within 5 years before the baseline visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
mprovement (reduction) in worst-itch numeric rating scale (WI-NRS) by ≥ 4 ; Proportion of participants with improvement (reduction) in worst-itch numeric rating scale (WI-NRS) by ≥4 from baseline to Week 12 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1 - Improvement (reduction) in worst-itch numeric rating scale (WI-NRS) by ≥ 4 ; Proportion of participants with improvement (reduction) in worst-itch numeric rating scale (WI-NRS) by ≥4 from baseline to Week 24 Proportion of participants with Investigator’s Global Assessment 0 or 1 score for PN-stage at Week 24 ; Proportion of participants with Investigator’s Global Assessment 0 or 1 score for PN-Stage (IGA PN-S) at Week 24. 2 - Time to onset of effect on pruritus ; Time to onset of effect on pruritus as measured by proportion of participants with an improvement (reduction) in WI-NRS by ≥4 from baseline during the 24-week treatment period 3 - Change from baseline in WI-NRS ; Change from baseline in WI-NRS at Week 12 and Week 24 4 - Percent change from baseline in WI-NRS ; Percent change from baseline in WI-NRS at Week 2, Week 4, Week 12 and Week 24 5 - Percent change from baseline in WI-NRS over time ; Percent change from baseline in WI-NRS over time until Week 24 6 - Proportion of participants with WI-NRS reduction ≥4 at Week 4 ; Proportion of participants with WI-NRS reduction ≥4 at Week 4 Proportion of participants with WI-NRS reduction ≥ 4 over time ; Proportion of participants with WI-NRS reduction ≥ 4 over time until Week 24 7 - Onset of action in change from baseline in WI-NRS ; Onset of action in change from baseline in WI-NRS (first p<0.05 difference from placebo in the daily WI-NRS that remains significant at subsequent measurements) until Week 12 8 - Proportion of participants with Investigator’s Global Assessment 0 or 1 score for PN-stage ; Proportion of participants with Investigator’s Global Assessment 0 or 1 score for PN-Stage (IGA PN-S) at Week 4, Week 8, and Week 12 9 - Change from baseline in IGA PN-S score ; Change from baseline in IGA PN-S score at Week 4, Week 8, Week 12 and Week 24 10 - Proportion of participants with Investigator’s Global Assessment 0 or 1 score for PN-Activity ; Proportion of participants with Investigator’s Global Assessment 0 or 1 score for PN-Activity (IGA PN-A) at Week 4, Week8, Week 12, and Week 24 11 - Change from baseline in health-related quality-of-life ; Change from baseline in health-related quality-of-life, as measured by Dermatology Life Quality Index (DLQI) to Week 12 and Week 24 12 - Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) from baseline through Week 24 ; Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) from baseline through Week 24 13 - Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab over time ; Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab over time |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1, 12,13 : Baseline to Week 24 2, 5 : Baseline to overtime until Week 24 3, 11 : Baseline to Week 12 and Week 24 4 : Baseline to Week 2, Week 4, Week 12 and Week 24 6 : Baseline to Week 4 Baseline to overtime until Week 24 7 : Baseline to overtime until Week 12 8 : Baseline to Week 4, Week 8 and Week 12 9, 10 : Baseline to Week 4, Week 8, Week 12, and Week 24
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
China |
Japan |
Korea, Republic of |
Mexico |
Russian Federation |
United States |
France |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |